心臟同步復律治療（CRT）被設計用于檢測室性心率不齊，保護心臟衰竭患者免于不恰當?shù)碾姄舯苊猱a(chǎn)生心室纖顫（AF）。

一種新型植入式心臟電復律器-除顫器（ICD），叫做Ovatio CRT-D，為單室或者雙室包括Parad軟件用于檢測心室纖顫。Parad能夠把患者由于AF接受不恰當治療的危險降低到0.3%。

Ovatio是由ELA公司研制開發(fā)的，屬于Sorin集團公司。第一例植入的是一位78歲的男性患者，患有冠狀動脈疾病導致的缺血性心機病。其它的植入手術計劃在法國、英國、丹麥和荷蘭進行。Ovatio已經(jīng)獲得了CE標記。Ovatio有柔軟的雙心室治療方案，包括心室~心室的調速功能。

Sorin集團商業(yè)部總裁Andre-Michel Ballester說：“Ovatio CRT-D投入使用是Sorin集團公司承諾為心臟衰竭患者開發(fā)最佳治療方案的又一明證。”Sorin集團在開發(fā)下述醫(yī)療技術中處于領先地位：心臟外科技術、心臟節(jié)律控制的創(chuàng)新治療方案、介入心臟病學以及慢性腎臟疾病。

New Cardioverter-Defibrillator
 
Cardiac resynchronization therapy (CRT) is designed to detect ventricular arrhythmias and protect heart failure patients from inappropriate shocks that may result from atrial fibrillation (AF).

A new implantable cardioverter-defibrillator (ICD), called Ovatio CRT-D, comes as a single chamber or a dual chamber and includes Parad software for the detection of ventricular arrhythmias. Parad has been shown to decrease a patient’s risk of receiving inappropriate therapy due to AF to only 0.3%.

Ovatio was developed by ELA (Munich, Germany), a Sorin Group company. The first implant was in a 78-year-old man with a history of ischemic cardiomyopathy due to coronary artery disease. Other implants are scheduled to take place in France, Great Britain, Denmark, and the Netherlands. The Ovatio has received the CE mark. Ovatio provides flexible biventricular therapy programming, including ventricle-to-ventricle timing.

“The introduction of Ovatio CRT-D is another illustration of the Sorin Group CRM’s commitment to delivering optimal care to the heart failure patient,” remarked Andre-Michel Ballester, president of the Sorin Group’s business unit. Sorin Group is a leading developer of medical technologies for cardiac surgery, innovative therapies for cardiac rhythm management, interventional cardiology, and the treatment of chronic kidney diseases.